Solid (TIMI 52)

A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 [SOLID-TIMI 52] Trial)Study Identifier: SB480848/033

Solid (TIMI 52) [NCT01000727]

Description: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 [SOLID-TIMI 52] Trial)Study Identifier: SB480848/033

Drug: Darapladib; Drug: Placebo

Primary Investigator: Kereiakes

Drug/Device Information
Darapladib(Lp-PLA2 inhibitor) versus placebo
Prevents necrotic plaque core progression
GlaxoSmithKline